,sacituzumab govitecan,,trastuzumab deruxtecan
gilead sciences,daiichi sankyo,astrazeneca,adicet bio
['enhertu', 'intrigue', 'tropics-02', 'adicet']
my only two #asco22 predictions this weekend (and admittedly these aren't going out on a limb). 1. enhertu will be asco22's biggest news.
2. tropics-02 will be so bad (&lt; 1 month pfs). i'm intrigued to see the adicet gamma delta update. also, a big moment for cd3 bi-specifics.
#Biotech investor, index provider, entrepreneur, creator of two Nasdaq-listed exchange traded funds, KC native, @univmiami hurricane.????